Summary
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PR+ breast cancer receiving letrozole as adjuvant therapy.
Register to download
Meeting Enrollment Goals Breast Cancer
You may also be interested in:
Webcast
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
View Resource
Fact Sheet
Data Monitoring Committee Unit
Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’…
View Resource
Blog
How Miles, Research, and Hope May Cure Cancer
Read Story
View all related content and resources for Oncology
Explore Insights